In vitro dendritic cell generation and lymphocyte subsets in myeloma patients: influence of thalidomide and high-dose chemotherapy treatment.
While vaccination with antigen-pulsed dendritic cells (DCs) represents a promising therapeutic strategy in multiple myeloma (MM), clinical benefit, so far, has been limited to individual patients. To identify potential problems with this approach, we have analyzed the influence of treatment paramete...
Main Authors: | Schütt, P, Buttkereit, U, Brandhorst, D, Lindemann, M, Schmiedl, S, Grosse-Wilde, H, Seeber, S, Nowrousian, MR, Opalka, B, Moritz, T |
---|---|
Format: | Journal article |
Language: | English |
Published: |
2005
|
Similar Items
-
Thalidomide in combination with dexamethasone for pretreated patients with multiple myeloma: serum level of soluble interleukin-2 receptor as a predictive factor for response rate and for survival.
by: Schütt, P, et al.
Published: (2005) -
Thalidomide in combination with vincristine, epirubicin and dexamethasone (VED) for previously untreated patients with multiple myeloma.
by: Schütt, P, et al.
Published: (2005) -
Immune parameters in multiple myeloma patients: influence of treatment and correlation with opportunistic infections.
by: Schütt, P, et al.
Published: (2006) -
Soluble MICA as an independent prognostic factor for the overall survival and progression-free survival of multiple myeloma patients.
by: Rebmann, V, et al.
Published: (2007) -
The clinical significance of soluble human leukocyte antigen class-I, ICTP, and RANKL molecules in multiple myeloma patients.
by: Schütt, P, et al.
Published: (2008)